VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,355,316 | +1.8% | 163,894 | -0.3% | 0.05% | +6.5% |
| Q2 2023 | $8,205,591 | +21.7% | 164,309 | -8.7% | 0.05% | 0.0% |
| Q1 2023 | $6,741,940 | -26.1% | 179,881 | -5.5% | 0.05% | -39.5% |
| Q4 2022 | $9,124,981 | +307.0% | 190,302 | +103.7% | 0.08% | +216.7% |
| Q3 2022 | $2,242,000 | +100.5% | 93,413 | +81.8% | 0.02% | +140.0% |
| Q2 2022 | $1,118,000 | -20.3% | 51,383 | -11.5% | 0.01% | +25.0% |
| Q1 2022 | $1,402,000 | +27.5% | 58,048 | +25.5% | 0.01% | +33.3% |
| Q4 2021 | $1,100,000 | +54.5% | 46,256 | +64.7% | 0.01% | +20.0% |
| Q3 2021 | $712,000 | -40.2% | 28,079 | -46.9% | 0.01% | -37.5% |
| Q2 2021 | $1,191,000 | -33.6% | 52,906 | -41.7% | 0.01% | -33.3% |
| Q1 2021 | $1,793,000 | +650.2% | 90,783 | +907.4% | 0.01% | +500.0% |
| Q4 2020 | $239,000 | – | 9,012 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |